Drug-induced hepatitis with severe cholestasis due to voglibose

International Hepatology Communications Pub Date : 1996-09-01 DOI:10.1016/0928-4346(96)00310-6

Toshikazu Masumoto, Maki Ishikawa, Yuusuke Yamauchi, Yoichi Hiasa, Kazuhiro Yamamoto, Hideto Iuchi, Keiji Ohkubo, S.M. Fazle Akbar, Kojiro Michitaka, Norio Horiike, Morikazu Onji

{"title":"Drug-induced hepatitis with severe cholestasis due to voglibose","authors":"Toshikazu Masumoto, Maki Ishikawa, Yuusuke Yamauchi, Yoichi Hiasa, Kazuhiro Yamamoto, Hideto Iuchi, Keiji Ohkubo, S.M. Fazle Akbar, Kojiro Michitaka, Norio Horiike, Morikazu Onji","doi":"10.1016/0928-4346(96)00310-6","DOIUrl":null,"url":null,"abstract":"<div><p>A case of drug-induced hepatitis with severe cholestasis caused by voglibose, a new agent for treating noninsulin-dependent diabetes mellitus, is described. The patient presented with icterus and pruritis. Voglibose was administered for 3 months before abnormal liver function was detected. The lymphocyte blast transformation test was positive for voglibose (stimulation index = 536%). One month after the onset of icterus, the patient also developed cholangitis due to methicillin-resistant <em>Staphylococcus aureus</em>, and the serum total bilirubin level increased to above 40 mg/dl. He was treated with plasma exchange, but eventually died. Voglibose is only absorbed slightly after oral administration, and there have been no reports of hepatitis due to this drug. This is the first fatal case of voglibose-induced hepatitis combined with methicillin-resistant <em>Staphylococcus aureus</em> cholangitis.</p></div>","PeriodicalId":13746,"journal":{"name":"International Hepatology Communications","volume":"5 4","pages":"Pages 289-296"},"PeriodicalIF":0.0000,"publicationDate":"1996-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0928-4346(96)00310-6","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Hepatology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0928434696003106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

A case of drug-induced hepatitis with severe cholestasis caused by voglibose, a new agent for treating noninsulin-dependent diabetes mellitus, is described. The patient presented with icterus and pruritis. Voglibose was administered for 3 months before abnormal liver function was detected. The lymphocyte blast transformation test was positive for voglibose (stimulation index = 536%). One month after the onset of icterus, the patient also developed cholangitis due to methicillin-resistant Staphylococcus aureus, and the serum total bilirubin level increased to above 40 mg/dl. He was treated with plasma exchange, but eventually died. Voglibose is only absorbed slightly after oral administration, and there have been no reports of hepatitis due to this drug. This is the first fatal case of voglibose-induced hepatitis combined with methicillin-resistant Staphylococcus aureus cholangitis.

查看原文本刊更多论文

药物性肝炎伴伏糖糖所致严重胆汁淤积

本文报道了一种治疗非胰岛素依赖型糖尿病的新药物——伏格糖糖引起的药物性肝炎合并严重胆汁淤积的病例。患者表现为黄疸和瘙痒。服药3个月后发现肝功能异常。淋巴细胞母细胞转化试验voglibose阳性(刺激指数为536%)。黄疸发病1个月后，患者又因耐甲氧西林金黄色葡萄球菌感染发生胆管炎，血清总胆红素升高至40 mg/dl以上。他接受了血浆置换治疗，但最终死亡。Voglibose在口服后仅被轻微吸收，并没有因该药引起肝炎的报道。这是第一例肝硬化合并耐甲氧西林金黄色葡萄球菌胆管炎的致命病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Hepatology Communications

自引率

0.00%

发文量